| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 9,0 € | -100.0% | 511,7 k € | — | — | |||||||||||||||||||
| Gross margin | 230,2 k € | +58.7% | 145,0 k € | -4.3% | 151,4 k € | +205.5% | 49,6 k € | -48.3% | 95,9 k € | +19.2% | 80,4 k € | -8.8% | 88,2 k € | -0.7% | 88,9 k € | +12.6% | 78,9 k € | +279.2% | 20,8 k € | +6615.5% | 310,0 € | -90.9% | 3,4 k € | +117.0% | -20,1 k € | +5.7% | -21,3 k € | -80.0% | -11,8 k € | -865.1% | -1,2 k € | -125.7% | 4,8 k € | -94.8% | 92,0 k € | +1074.8% | -9,4 k € | -224.7% | -2,9 k € | |
| EBITDA | 154,2 k € | +196.3% | 52,1 k € | -43.6% | 92,3 k € | +2960.7% | -3,2 k € | -107.1% | 45,7 k € | +69.5% | 27,0 k € | -57.5% | 63,5 k € | -25.4% | 85,1 k € | +13.2% | 75,2 k € | +338.6% | 17,2 k € | +625.4% | -3,3 k € | -2713.8% | -116,0 € | +99.6% | -26,8 k € | -8.4% | -24,7 k € | -48.4% | -16,7 k € | -180.5% | -5,9 k € | -342.6% | 2,5 k € | -96.6% | 71,4 k € | +374.5% | -26,0 k € | -34.5% | -19,3 k € | |
| Operating profit | 76,7 k € | +287.4% | -40,9 k € | -3292.4% | 1,3 k € | +101.4% | -93,8 k € | -109.7% | -44,8 k € | +29.2% | -63,2 k € | -139.6% | -26,4 k € | -131.0% | 85,1 k € | +13.2% | 75,2 k € | +338.6% | 17,2 k € | +625.4% | -3,3 k € | +20.7% | -4,1 k € | +86.6% | -30,8 k € | +69.3% | -100,2 k € | -28.0% | -78,3 k € | -27.9% | -61,2 k € | -41.4% | -43,3 k € | -204.0% | 41,6 k € | +259.8% | -26,0 k € | -34.5% | -19,3 k € | |
| Profit/loss | 77,5 k € | +291.1% | -40,6 k € | -2965.1% | 1,4 k € | +101.5% | -93,9 k € | -109.5% | -44,8 k € | +29.2% | -63,3 k € | -139.3% | -26,5 k € | -118.2% | 145,1 k € | +93.0% | 75,2 k € | +1675.5% | 4,2 k € | +110.6% | -39,8 k € | -14.3% | -34,8 k € | +36.3% | -54,7 k € | +54.7% | -120,6 k € | -52.1% | -79,3 k € | -21.1% | -65,5 k € | -37.8% | -47,5 k € | -210.8% | 42,9 k € | +265.0% | -26,0 k € | -35.3% | -19,2 k € | |
| Equity | 815,7 k € | +10.5% | 738,1 k € | -5.2% | 778,7 k € | +0.2% | 777,3 k € | -10.8% | 871,2 k € | -4.9% | 916,1 k € | -6.5% | 979,4 k € | -2.6% | 1,0 M € | +16.9% | 860,8 k € | +9.6% | 785,6 k € | +4320.6% | -18,6 k € | -187.8% | 21,2 k € | -62.2% | 56,0 k € | -49.4% | 110,7 k € | -52.1% | 231,4 k € | -25.5% | 310,7 k € | -17.4% | 376,1 k € | -11.2% | 423,7 k € | +11.3% | 380,8 k € | -6.4% | 406,8 k € | |
| Total assets | 859,4 k € | +11.9% | 768,0 k € | -5.3% | 810,7 k € | +3.0% | 786,8 k € | -10.6% | 880,5 k € | -7.4% | 950,9 k € | -3.2% | 982,6 k € | -6.2% | 1,0 M € | -2.2% | 1,1 M € | -1.2% | 1,1 M € | +5.2% | 1,0 M € | +0.1% | 1,0 M € | +1.6% | 1,0 M € | +37.9% | 734,5 k € | +9.7% | 669,6 k € | -3.1% | 691,1 k € | +6.2% | 650,5 k € | +20.9% | 537,9 k € | +19.9% | 448,7 k € | +0.2% | 447,9 k € | |
| Cash | 409,1 k € | +67.6% | 244,1 k € | +61.1% | 151,5 k € | +51.2% | 100,2 k € | -3.9% | 104,3 k € | +96.0% | 53,2 k € | +65.2% | 32,2 k € | +332.5% | 7,4 k € | -39.1% | 12,2 k € | +5285.5% | 227,0 € | -81.7% | 1,2 k € | +1671.4% | 70,0 € | -97.9% | 3,4 k € | +39.4% | 2,4 k € | +1032.2% | 214,0 € | -83.1% | 1,3 k € | +115.1% | 589,0 € | -69.9% | 2,0 k € | +4.9% | 1,9 k € | -4.5% | 2,0 k € | |
| Debts | 43,8 k € | +46.6% | 29,9 k € | -6.7% | 32,0 k € | +234.8% | 9,6 k € | +2.7% | 9,3 k € | -73.3% | 34,8 k € | +998.4% | 3,2 k € | -92.4% | 41,7 k € | -80.2% | 210,9 k € | -29.5% | 299,1 k € | -71.5% | 1,0 M € | +4.1% | 1,0 M € | +5.4% | 957,0 k € | +53.4% | 623,8 k € | +42.3% | 438,2 k € | +15.2% | 380,4 k € | +38.7% | 274,4 k € | +140.1% | 114,3 k € | +68.2% | 68,0 k € | +65.1% | 41,2 k € | |
| Staff | — | — | — | — | — | 1 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||
Public limited company · Mons · incorporated on 31/12/1983
Public limited company profitable and well capitalised. Cash position rising (+67.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
GESTIPHARMA is a Public limited company incorporated in 1983. Its main activity is: Management consultancy activities. Its registered office is in Mons.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette